CrystalsFirst

Executive Summary

CrystalsFirst is a Berlin-based biotechnology company founded in 2018 that is redefining small-molecule drug discovery through its proprietary MAGNET platform. This platform integrates high-throughput structural biology, including crystallographic fragment screening, with AI-powered drug design to accelerate target-to-hit, hit-to-lead, and lead optimization programs. Operating as a service provider and integrated research partner for biotech and pharmaceutical companies, CrystalsFirst offers a unique value proposition: combining experimental structural data with computational predictions to reduce cycle times and improve success rates in early drug discovery. The company's approach addresses a critical bottleneck in the pharmaceutical industry—the high attrition rate of small-molecule candidates due to poor target engagement or suboptimal pharmacokinetics. By providing structural insights at scale, CrystalsFirst enables its partners to make better-informed decisions earlier in the discovery process, thereby increasing the probability of clinical success. Despite being a relatively young company, CrystalsFirst has established itself in the competitive drug discovery services market, leveraging Germany's strong biotech ecosystem and Berlin's growing life sciences hub. The company's management team brings deep expertise in structural biology and computational chemistry, positioning the firm to capture a share of the growing demand for integrated drug discovery solutions. While financial details and specific collaborations are not publicly disclosed, the company's business model—as a fee-for-service and milestone-based partner—provides a scalable and recurring revenue stream. CrystalsFirst is well-positioned to benefit from the trend toward outsourcing early discovery to specialized providers. However, the company faces competition from established CROs and AI-driven drug discovery platforms. Key risks include execution of partnerships, technological differentiation, and the ability to scale its team and infrastructure to meet growing demand.

Upcoming Catalysts (preview)

• H2 2026Announcement of Major Pharma Collaboration40% success
• 2026Series A Funding Round50% success
• H1 2026Validation Study Publication in Peer-Reviewed Journal60% success